North-America age-related macular degeneration (AMD) market is projected to register a CAGR of 8.0% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.
Market Segmentation:
North-America Age-Related Macular Degeneration (AMD) Market, By Types (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, and Others) and Distribution Channel (Direct Tender and Retail Sales) Industry Trends and Forecast to 2029.
Some of the major factors contributing to the growth of the North-America age-related macular degeneration (AMD) market are:
Growing geriatric population
Growing prevalence of macular degeneration
Market Players:
The key market players for North-America age- related macular degeneration (AMD) market are listed below:
Novartis AG
Bayer AG
REGENXBIO Inc.
Ionis Pharmaceutics
Ocugen Inc
Johnson & Johnson Services, Inc
IVERIC bio
MeiraGTx Limited
Adverum Biotechnologies, Inc.
Graybug Vision Inc.
Kodiak Sciences Inc.
Genentech Inc.
TABLE OF CONTENTS
1 INTRODUCTION 13
- 1.1 OBJECTIVES OF THE STUDY 13
- 1.2 MARKET DEFINITION 13
- 1.3 OVERVIEW OF NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET 13
- 1.4 LIMITATIONS 15
- 1.5 MARKETS COVERED 15
2 MARKET SEGMENTATION 18
- 2.1 MARKETS COVERED 18
- 2.2 GEOGRAPHICAL SCOPE 19
- 2.3 YEARS CONSIDERED FOR THE STUDY 20
- 2.4 CURRENCY AND PRICING 20
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 21
- 2.6 MULTIVARIATE MODELLING 24
- 2.7 TYPE LIFELINE CURVE 24
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 25
- 2.9 DBMR MARKET POSITION GRID 26
- 2.10 MARKET END USER COVERAGE GRID 27
- 2.11 VENDOR SHARE ANALYSIS 28
- 2.12 SECONDARY SOURCES 29
- 2.13 ASSUMPTIONS 29
3 EXECUTIVE SUMMARY 30
4 PREMIUM INSIGHTS 33
- 4.1 PESTEL 34
- 4.2 PORTER'S FIVE FORCES MODEL 35
5 REGULATORY FRAMEWORK 36
6 MARKET OVERVIEW 39
- 6.1 DRIVERS 41
- 6.1.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION 41
- 6.1.2 INCREASING GERIATRIC POPULATION 41
- 6.1.3 INCREASE IN PIPELINE PRODUCTS 42
- 6.1.4 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYERS 43
- 6.2 RESTRAINTS 43
- 6.2.1 HIGH COST OF TREATMENT AND PROCEDURES 43
- 6.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS 44
- 6.3 OPPORTUNITIES 45
- 6.3.1 INCREASING RESEARCH AND DEVELOPMENT 45
- 6.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE OF AMD 45
- 6.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT 46
- 6.3.4 INCREASING PRODUCT APPROVAL FOR AGE-RELATED MACULAR DEGENERATION (AMD) 46
- 6.4 CHALLENGES 47
- 6.4.1 LIMITED ACCESS TO TREATMENT 47
- 6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR PRODUCTS 47
7 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE 48
- 7.1 OVERVIEW 49
- 7.2 DRY AMD 52
- 7.3 WET AMD 52
- 7.3.1 MEDICATIONS 53
- 7.3.2 ANTI-VEGF THERAPY 54
- 7.3.3 GENE THERAPY 54
- 7.3.4 SURGERY 54
8 NORTH AMERICA AGE- RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER 55
- 8.1 OVERVIEW 56
- 8.2 HOSPITALS 59
- 8.3 SPECIALTY CLINICS 59
- 8.4 AMBULATORY SURGICAL CENTERS 60
- 8.5 HOME HEALTHCARE 61
- 8.6 OTHERS 62
9 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL 63
- 9.1 OVERVIEW 64
- 9.2 RETAIL SALES 68
- 9.2.1 HOSPITAL PHARMACIES 69
- 9.2.2 RETAIL PHARMACIES 69
- 9.2.3 OTHERS 69
- 9.3 DIRECT TENDER 69
10 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION 70
- 10.1 NORTH AMERICA 71
- 10.1.1 U.S. 77
- 10.1.2 CANADA 79
- 10.1.3 MEXICO 81
11 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY LANDSCAPE 83
- 11.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 83
12 SWOT ANALYSIS 84
13 COMPANY PROFILE 85
- 13.1 NOVARTIS AG 85
- 13.1.1 COMPANY SNAPSHOT 85
- 13.1.2 REVENUE ANALYSIS 85
- 13.1.3 COMPANY SHARE ANALYSIS 86
- 13.1.4 PRODUCT PORTFOLIO 86
- 13.1.5 RECENT DEVELOPMENT 86
- 13.2 GENENTECH, INC. 87
- 13.2.1 COMPANY SNAPSHOT 87
- 13.2.2 COMPANY SHARE ANALYSIS 87
- 13.2.3 PRODUCT PORTFOLIO 88
- 13.2.4 RECENT DEVELOPMENT 88
- 13.3 BAYER AG 89
- 13.3.1 COMPANY SNAPSHOT 89
- 13.3.2 REVENUE ANALYSIS 89
- 13.3.3 COMPANY SHARE ANALYSIS 90
- 13.3.4 PRODUCT PORTFOLIO 90
- 13.3.5 RECENT DEVELOPMENT 90
- 13.4 ADVERUM BIOTECHNOLOGIES, INC. 91
- 13.4.1 COMPANY SNAPSHOT 91
- 13.4.2 REVENUE ANALYSIS 91
- 13.4.3 PRODUCT PORTFOLIO 91
- 13.4.4 RECENT DEVELOPMENT 92
- 13.5 ASTELLAS PHARMA INC. 93
- 13.5.1 COMPANY SNAPSHOT 93
- 13.5.2 REVENUE ANALYSIS 93
- 13.5.3 PRODUCT PORTFOLIO 94
- 13.5.4 RECENT DEVELOPMENT 94
- 13.6 GRAYBUG VISION INC. 95
- 13.6.1 COMPANY SNAPSHOT 95
- 13.6.2 REVENUE ANALYSIS 95
- 13.6.3 PRODUCT PORTFOLIO 95
- 13.6.4 RECENT DEVELOPMENT 96
- 13.7 GENSIGHT BIOLOGICS 97
- 13.7.1 COMPANY SNAPSHOT 97
- 13.7.2 REVENUE ANALYSIS 97
- 13.7.3 PRODUCT PORTFOLIO 98
- 13.7.4 RECENT DEVELOPMENTS 98
- 13.7.4.1 EVENT 98
- 13.7.4.2 AWARD 98
- 13.8 IONIS PHARMACEUTICALS 99
- 13.8.1 COMPANY SNAPSHOT 99
- 13.8.2 REVENUE ANALYSIS 99
- 13.8.3 PRODUCT PORTFOLIO 100
- 13.8.4 RECENT DEVELOPMENT 100
- 13.9 IVERIC BIO 101
- 13.9.1 COMPANY SNAPSHOT 101
- 13.9.2 PRODUCT PORTFOLIO 101
- 13.9.3 RECENT DEVELOPMENT 101
- 13.10 JOHNSON &JOHNSON SERVICES, INC. 102
- 13.10.1 COMPANY SNAPSHOT 102
- 13.10.2 REVENUE ANALYSIS 102
- 13.10.3 PRODUCT PORTFOLIO 103
- 13.10.4 RECENT DEVELOPMENT 103
- 13.10.4.1 COLLABORATION 103
- 13.11 KODIAK SCIENCES INC. 104
- 13.11.1 COMPANY SNAPSHOT 104
- 13.11.2 PRODUCT PORTFOLIO 104
- 13.11.3 RECENT DEVELOPMENT 104
- 13.12 MEIRAGTX LIMITED 105
- 13.12.1 COMPANY SNAPSHOT 105
- 13.12.2 PRODUCT PORTFOLIO 105
- 13.12.3 RECENT DEVELOPMENTS 105
- 13.12.3.1 EVENTS 105
- 13.12.3.2 AWARD 106
- 13.12.3.3 COLLABORATION 106
- 13.13 OCUGEN INC. 107
- 13.13.1 COMPANY SNAPSHOT 107
- 13.13.2 PRODUCT PORTFOLIO 107
- 13.13.3 RECENT DEVELOPMENTS 107
- 13.13.3.1 INVESTMENT 107
- 13.13.3.2 CLINICAL TRIAL 108
- 13.14 PIXIUM VISION 109
- 13.14.1 COMPANY SNAPSHOT 109
- 13.14.2 REVENUE ANALYSIS 109
- 13.14.3 PRODUCT PORTFOLIO 109
- 13.14.4 RECENT DEVELOPMENT 110
- 13.15 REGENXBIO INC. 111
- 13.15.1 COMPANY SNAPSHOT 111
- 13.15.2 PRODUCT PORTFOLIO 111
- 13.15.3 RECENT DEVELOPMENTS 111
- 13.15.3.1 EVENT 111
- 13.15.3.2 COLLABORATION 112
- 13.15.3.3 CERTIFICATION 112
14 QUESTIONNAIRE 113
15 RELATED REPORTS 116